Список литературы

1. Neufeld E., Muenzer J. The mucopolysaccharidoses//In: Scriver CR, Beaudet AL, Sly WS, Valle D, Childs B, Kinzler KW, Vogelstein B, eds. The Metabolic and Molecular Basis of Inherited Disease. 8 ed. New York. NY: McGraw-Hill. 2001. P. 3421 - 52.

2. Scarpa M, Z, Beck M, et al. Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis. 2011; 6: 72. Published 2011 Nov 7. doi: 10.1186/1750-1172-6-72.

3. Muenzer J, Jones SA, A, et al. Ten years of the Hunter Outcome Survey (HOS): insights, achievements, and lessons learned from a global patient registry. Orphanet J Rare Dis. 2017; 12(1): 82. Published 2017 May 2. doi: 10.1186/s13023-017-0635-z.

4. Meikle P.J., Hopwood J.J., Clague A.E., Carey W.F. Prevalence of lysosomal storage disorders//JAMA. 1999. V. 281. P. 249 - 54.

5. Martin R, Beck M, Eng C, et al. Recognition and diagnosis of mucopolysaccharidosis II (Hunter syndrome). Pediatrics. 2008; 121(2): e377 - e386. doi: 10.1542/peds.2007-1350.

6. Simmons MA, Bruce IA, Penney S, Wraith E, Rothera MP. Otorhinolaryngological manifestations of the mucopolysaccharidoses. Int J Pediatr Otorhinolaryngol. 2005; 69(5): 589 - 595. doi: 10.1016/j.ijporl.2005.01.017.

7. Biswas J., Nandi K., Sridharan S., Ranjan P. Ocular manifestation of storage diseases//Curr. Opin. Ophthalmol. 2008. V. 19. P. 507 - 11.

8. Thappa D. M., Singh A., Jaisankar T. J., Rao R., Ratnakar C. Pebbling of the Skin: A Marker of Hunter's Syndrome//Pediatric Dermatology. 1998. V. 15. N 5. P. 370 - 3.

9. Barbier A.J., Bielefeld B., Whiteman D.A. et al. The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase//Mol Genet Metab. 2013. V. 110. N 3. P. 303 - 10.

10. Kim C., Seo J., Chung Y., Ji H.J., Lee J., Sohn J. Comparative study of idursulfase beta and idursulfase in vitro and in vivo//J. Hum. Genet. 2017. V. 62. P. 167 - 74.

11. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders//Int J Clin Pharmacol Ther. 2009. V. 47. N 1. P. 100 - 6.

12. Wraith JE, Scarpa M, Beck M, et al. Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr. 2008; 167(3): 267 - 277. doi: 10.1007/s00431-007-0635-4.

13. Sampayo-Cordero M, Miguel-Huguet B, Pardo-Mateos A, et al. Agreement between results of meta-analyses from case reports and clinical studies, regarding efficacy and safety of idursulfase therapy in patients with mucopolysaccharidosis type II (MPS-II). A new tool for evidence-based medicine in rare diseases. Orphanet J Rare Dis. 2019; 14(1): 230. Published 2019 Oct 21. doi: 10.1186/s13023-019-1202-6.

14. Bradley LA, Haddow HRM, Palomaki GE. Treatment of mucopolysaccharidosis type II (Hunter syndrome): results from a systematic evidence review. Genet Med. 2017; 19(11): 1187 - 1201. doi: 10.1038/gim.2017.30.

15. da Silva EM, Strufaldi MW, Andriolo RB, Silva LA. Enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II (Hunter syndrome). Cochrane Database Syst Rev. 2016; 2(2): CD008185. Published 2016 Feb 5. doi: 10.1002/14651858.CD008185.pub4.

16. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010; 33(4): 589 - 604. doi: 10.1590/S1415 - 47572010005000093.

17. Rezende M. M. et al. Brazilian reference values for MPS II screening in dried blood spots-A fluorimetric assay//Clinical biochemistry. 2014. V. 47. N 13 - 14. P. 1297 - 9.

18. Human Gene Mutations Database. Qiagen HGMD Professional

19. Okuyama T., Tanaka A., Suzuki Y. et al. Japan Elaprase Treatment (JET) study: idursulfase enzyme replacement therapy in adult patients with attenuated Hunter syndrome (mucopolysaccharidosis II, MPS II)//Mol Genet Metab. 2010. V. 99. P. 18 - 25.

20. Guffon N., Heron B., Chabrol B. Diagnosis, quality of life, and treatment of patients with Hunter syndrome in the French healthcare system: a retrospective observational study//Orphanet J Rare Dis. 2015. V. 10. P. 43.

21. Jurecka A., Zuberuber Z., Opoka-Winiarska V. et al. Effect of rapid cessation of enzyme replacement therapy: a report of 5 cases and a review of the literature//Mol Genet Metab. 2012. V. 107. P. 508 - 12.

22. Миронов С.П., Колесов С.В., Переверзев В.С., Колбовский Д.А., Кулешов А.А., Ветрилэ М.С., Казьмин А.И. Опыт хирургического лечения краниовертебрального стеноза у пациентов с мукополисахаридозом I, II, VI типов//Хирургия позвоночника. 2018. Т. 15. N 4. С. 32 - 40.

23. Williams N., Challoumas D., Eastwood D. M. Does orthopaedic surgery improve quality of life and function in patients with mucopolysaccharidoses?//Journal of Children's Orthopaedics. 2017. V. 11. N 4. P. 289 - 97.

24. Miebach E. Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther. 2009; 47 Suppl 1: S100 - S106. doi: 10.5414/cpp47100.

25. Mendelsohn N. J., Harmatz P., Bodamer O. et al. Importance of surgical history in diagnosing mucopolysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey//Genetics in Medicine. 2010. V. 12. N 12. P. 816 - 22.

26. Remondino R. G. et al. Clinical Manifestations and Surgical Management of Spinal Lesions in Patients With Mucopolysaccharidosis: A Report of 52 Cases//Spine deformity. 2019. V. 7. N. 2. P. 298 - 303.

27. Kwon JY, Ko K, Sohn YB, et al. High prevalence of carpal tunnel syndrome in children with mucopolysaccharidosis type II (Hunter syndrome). Am J Med Genet A. 2011; 155A: 1329 - 1335

28. Giugliani R, Federhen A, Rojas MV, et al. Mucopolysaccharidosis I, II, and VI: Brief review and guidelines for treatment. Genet Mol Biol. 2010; 33(4): 589 - 604.

29. Yoon JH, Lee HI, Jang JH, et al. Oral manifestation and root canal therapy of the patient with mucopolysaccharidosis. Restor Dent Endod. 2019; 44(2): e14. Published 2019 Apr 4. doi: 10.5395/rde.2019.44. e14

30. Вашакмадзе Н.Д. Мультидисциплинарные принципы ведения детей с мукополисахаридозами в повышении эффективности их диагностики и лечения: автореферат дис. ...доктора медицинских наук: 14.01.08, Екатеринбург, 2019. - 47 с.

31. Lin HY, Shih SC, Chuang CK, Chen MR, Niu DM, Lin SP. Assessment of bone mineral density by dual energy x-ray absorptiometry in patients with mucopolysaccharidoses. Orphanet J Rare Dis. 2013; 8: 71. Published 2013 May 11. doi: 10.1186/1750-1172-8-71.

32. Ватанская И.Ю., Стрекозова И.П., & Котелевская И.Т. (2016). Мукополисахаридоз II типа в практике терапевта. Актуальная инфектология, (3 (12)), 93 - 99. doi: 10.22141/2312-413x.3.12.2016.81721

33. T, N, Schelle T, A, Muschol N. Nerve ultrasound in clinical management of carpal tunnel syndrome in mucopolysaccharidosis. Dev Med Child Neurol. 2016; 58(11): 1172 - 1179. doi: 10.1111/dmcn.13127

34. Silveira MRMD, Buriti AKL, Martins AM, Gil D, Azevedo MF. Audiometric evaluation in individuals with mucopolysaccharidosis. Clinics (Sao Paulo). 2018; 73: e523. Published 2018 Dec 3. doi: 10.6061/clinics/2018/e523

35. Muenzer J, Beck M, Eng CM, et al. Multidisciplinary management of Hunter syndrome. Pediatrics. 2009; 124(6): e1228 - e1239. doi: 10.1542/peds.2008-0999

36. Scarpa M, CM, Amartino H. Epilepsy in mucopolysaccharidosis disorders. Mol Genet Metab. 2017; 122S: 55 - 61. doi: 10.1016/j.ymgme.2017.10.006

37. Mitchell J, Berger KI, Borgo A, et al. Unique medical issues in adult patients with mucopolysaccharidoses. Eur J Intern Med. 2016; 34: 2 - 10. doi: 10.1016/j.ejim.2016.05.017

38. J, M, C, Morales-Conejo M, Ceberio-Hualde L, Del Toro M. Efficacy of Idursulfase therapy in patients with Mucopolysaccharidosis type II who initiated enzyme replacement therapy in adult age. A systematic review of the literature. Mol Genet Metab. 2018; 124(3): 216 - 227. doi: 10.1016/j.ymgme.2018.04.013

39. Giugliani R, Villarreal ML, Valdez CA, et al. Guidelines for diagnosis and treatment of Hunter Syndrome for clinicians in Latin America. Genet Mol Biol. 2014; 37(2): 315 - 329. doi: 10.1590/s1415-47572014000300003

40. Lysosomal Storage Diseases: Early Diagnosis and New Treatments. R. Parini, G. Andria, John Libbey Eurotext, 2010, pp. 73 - 80

41. Politei JM, G, Guelbert NB, et al. Recommendations for Evaluation and Management of Pain in Patients With Mucopolysaccharidosis in Latin America. J Pain Symptom Manage. 2018; 56(1): 146 - 152. doi: 10.1016/j.jpainsymman.2018.03.023

42. Faragher MW, Stark RJ. Hunter syndrome complicated by hydrocephalus and an endogenous anticoagulant. J Clin Neurosci. 1997; 4(2): 252 - 255. doi:10.1016/s0967-5868(97)90083-7

43. Scarpa M. Mucopolysaccharidosis Type II. 2007 Nov 6 [Updated 2018 Oct 4]. In: Adam MP, Everman DB, Mirzaa GM, et al., editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993 - 2022. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1274/.

44. Piraud M, Boyer S, Mathieu M, Maire I. Diagnosis of mucopolysaccharidoses in a clinically selected population by urinary glycosaminoglycan analysis: a study of 2,000 urine samples. Clin Chim Acta. 1993; 221(1-2): 171 - 181. doi: 10.1016/0009-8981(93)90031-x

45. Christianto A, Watanabe H, Nakajima T, Inazu T. Idursulfase enzyme replacement therapy in an adult patient with severe Hunter syndrome having a novel mutation of iduronate-2-sulfatase gene. Clin Chim Acta. 2013; 423: 66 - 68. doi: 10.1016/j.cca.2013.04.022

46. Moreira GA, Kyosen SO, Patti CL, Martins AM, Tufik S. Prevalence of obstructive sleep apnea in patients with mucopolysaccharidosis types I, II, and VI in a reference center. Sleep Breath. 2014; 18(4): 791 - 797. doi: 10.1007/s11325-014-0944-6

47. Рекомендация Коллегии Евразийской экономической комиссии от 13.09.2021 N 23 "О Руководстве по определению возможности использования лекарственной формы лекарственного препарата в педиатрической практике или в отношении отдельной группы педиатрической популяции в целях указания соответствующих сведений в общей характеристике лекарственного препарата и инструкции по медицинскому применению"

48. Приказ Росздравнадзора от 04.05.2021 N 3881 "Об утверждении Ведомственной программы профилактики нарушений обязательных требований при осуществлении государственного контроля качества и безопасности медицинской деятельности, федерального государственного надзора в сфере обращения лекарственных средств и государственного контроля за обращением медицинских изделий"

49. "МУ 3.3.2.2437-09. 3.3.2. Медицинские иммунобиологические препараты. Применение термоиндикаторов для контроля температурного режима хранения и транспортирования медицинских иммунобиологических препаратов в системе "холодовой цепи". Методические указания" (утв. Главным государственным санитарным врачом РФ 21.01.2009).

50. Naur OM, Anggraini A, Indraswari BW, Wandita S, Wibowo T, Haksari EL. Immunisation issues in patient with mucopolysaccharidosis: A case report. Med J Malaysia. 2020 May; 75 (Suppl 1): 51 - 52

51. Ramos BCF, Aranda CS, Cardona RSB, Martins AM, D, Clemens SAC, Clemens R. Vaccination strategies for people living with inborn errors of metabolism in Brazil. J Pediatr (Rio J). 2023 Mar - Apr; 99 Suppl 1 (Suppl 1): S70 - S80

52. M, Canda E, H, Erdem F, P, Bal Sahbudak Z, Kalkan S, M. COVID-19 and Vaccination Status in Lysosomal Storage Diseases: A Single-Center Experience. Turk Arch Pediatr. 2023 May; 58(3): 262 - 267

53. Lau H, Harmatz P, Botha J, Audi J, Link B. Clinical characteristics and somatic burden of patients with mucopolysaccharidosis II with or without neurological involvement: An analysis from the Hunter Outcome Survey. Mol Genet Metab Rep. 2023 Sep 8; 37:101005. doi: 10.1016/j.ymgmr.2023.101005. PMID: 38053935; PMCID: PMC10694755.

54. D'Avanzo F, Rigon L, Zanetti A, Tomanin R. Mucopolysaccharidosis Type II: One Hundred Years of Research, Diagnosis, and Treatment. International Journal of Molecular Sciences. 2020; 21(4): 1258. https://doi.org/10.3390/ijms21041258.

55. Scarpa M, Lampe C. Mucopolysaccharidosis Type II. 2007 Nov 6 [Updated 2025 Jan 16]. In: Adam MP, Feldman J, Mirzaa GM, et al., editors. GeneReviews(R) [Internet]. Seattle (WA): University of Washington, Seattle; 1993 - 2025. Available from: https://www.ncbi.nlm.nih.gov/books/NBK1274/

56. Borgo, A., Cossio, A., Gallone, D. et al. Orthopaedic challenges for mucopolysaccharidoses. Ital J Pediatr 44 (Suppl 2), 123 (2018). https://doi.org/10.1186/s13052-018-0557-y